RWE, Market Access, Pricing & Reimbursement Global Congress 2021 Europe
Agenda at a Glance
Day 1 - Congress
Day 1: Thursday 7th October 2021
CURRENT TRENDS & STRATEGIES
- Reforms to National Reimbursement system and pricing processes in Europe
Updates to Managed Entry and Early Access Pathways
Greater adoption of Real World Evidence (RWE)
Increase Cross-Border Collaboration as a potential means of controlling cost
- What is the potential effect of leaving the EU
- Understanding the priorities for negotiations
- Is there a long term solution that provides legal certainty and compliance
- What are the contingency plans for the Pharmaceutical industry?
- Understand the impact of RWE decisions on price and market access
- The shift from RCT to RWE; closing the gap
- RWE strategies
- Discuss the role of RWE in understanding and confronting the pandemic
- Focus on the role of data collection, visualization and communication
- Recognising differing data generation expectations across various stakeholders
- Strategise new data collection opportunities in a virtual/remote world
Stream Sessions - Choose between 2 topic streams
Real-World Evidence - Stream Session
MA, Pricing & Reimbursement - Stream Session
- Understanding the risks & opportunities to both
payer and industry - How does real-world evidence help ensure
market access?
- How are patient registries used to generate realworld
data for rare diseases and orphan drugs - Does different stakeholder types have different
- RWE information needs for decision making?
- How can manufacturers use data to build an
effective real-world evidence plan
- Challenges and barriers to market access across
Europe - What is the current mood amongst payers?
- How effective is the market access strategies in
the current climate?
- The impact of AMNOG reforms on prices
- Importance of early benefit assessment
- Outlook and suggestions
- Go beyond clinical trial results to make your
product stand out - Build customer advocacy through superior
customer experience - New drug launches today require greater
coordination across the entire organization
3:50 pm - Afternoon Break & Networking
- Recent advances in digital and advanced
analytics for RWE generation - What role can it play across the pharma value
chain? - What does it take to deliver?
- What are the important aspects involved in
utilising RWE to support product effectiveness? - How can this be used to advance reimbursement
model?
- Why are PRO measures crucial to optimal market
access? - How to properly use PRO effectively to have apositive impact on reimbursement decisions?
- Identify the main barriers
- Create new strategies to overcome them
- Current state of Biosimilars in EU, what future
brings?